Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;14(2):261-267.
doi: 10.3233/JPD-230331.

Striatal Serotonin 4 Receptor is Increased in Experimental Parkinsonism and Dyskinesia

Affiliations

Striatal Serotonin 4 Receptor is Increased in Experimental Parkinsonism and Dyskinesia

Rossella Cirillo et al. J Parkinsons Dis. 2024.

Abstract

Alterations of serotonin type 4 receptor levels are linked to mood disorders and cognitive deficits in several conditions. However, few studies have investigated 5-HT4R alterations in movement disorders. We wondered whether striatal 5-HT4R expression is altered in experimental parkinsonism. We used a brain bank tissue from a rat and a macaque model of Parkinson's disease (PD). We then investigated its in vivo PET imaging regulation in a cohort of macaques. Dopaminergic depletion increases striatal 5-HT4R in the two models, further augmented after dyskinesia-inducing L-Dopa. Pending confirmation in PD patients, the 5-HT4R might offer a therapeutic target for dampening PD's symptoms.

Keywords: L-Dopa; PET imaging; Parkinson’s disease; dyskinesia; experimental animal models; immunohistochemistry; movement disorders; parkinsonism; serotonin.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to report.

Erwan Bezard is an Editorial Board Member of this journal but was not involved in the peer-review process of this article nor had access to any information regarding its peer-review.

Figures

Fig. 1
Fig. 1
Striatal upregulation of 5-HT4R after dopamine depletion and L-Dopa exposure in the 6-OHDA lesioned rat. A) Histogram represents optical density measurements of 5-HT4R (in arbitrary units) in the ipsilateral dorsolateral striatum for the 3 experimental groups. **p < 0.01 versus control; &&&p < 0.001 versus parkinsonian. B) Photomicrographs at high magnification (x16) of coronal sections of a dyskinetic rat, exemplifying spatio-temporal concomitance of 5-HT4R and FosB increases in the ipsilateral dorsolateral striatum. Scale bar on B is 50μm. OD, optical density, Park, parkinsonian; Dysk, dyskinetic.
Fig. 2
Fig. 2
Striatal upregulation of 5-HT4R after dopamine depletion and L-Dopa exposure in MPTP-treated macaques. A) Histogram represents optical density measurements of 5-HT4R (in arbitrary units) in the posterior putamen for the 3 experimental groups. *p < 0.05 versus control; &p < 0.05 versus parkinsonian. B) [11C]PE2I PET averaged images (in color) on coronal planes at the level of the posterior caudate and putamen for each condition. C) Histogram represents 11C-PE2I BPND in the posterior putamen for each condition. D) [11C]SB207145 PET averaged images (in color) on coronal planes at the level of the posterior caudate and putamen for each condition. E) Histogram represents 11C-SB207145 BPND in the posterior putamen for each condition. *p < 0.05, **p < 0.01 versus baseline. Color represents the level of BPND using the cerebellum as the reference region (red indicates high whereas bleu indicates low BPND on each scale). a.u., arbitrary units; BPND, non-displaceable binding potential; Dysk, dyskinetic; OD, optical density; Park, parkinsonian.

References

    1. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA (2009) Initial clinical manifestations of Parkinson’s disease: Features and pathophysiological mechanisms. Lancet Neurol 8, 1128–1139. - PubMed
    1. Pagano G, Niccolini F, Fusar-Poli P, Politis M (2017) Serotonin transporter in Parkinson’s disease: A meta-analysis of positron emission tomography studies. Ann Neurol 81, 171–180. - PubMed
    1. Maillet A, Krack P, Lhommée E, Météreau E, Klinger H, Favre E, Le Bars D, Schmitt E, Bichon A, Pelissier P, Fraix V, Castrioto A, Sgambato-Faure V, Broussolle E, Tremblay L, Thobois S (2016) The prominentrole of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain 139(Pt 9), 2486–2502. - PubMed
    1. Pagano G, Niccolini F, Politis M (2018) The serotonergic system in Parkinson’s patients with dyskinesia: Evidence from imaging studies. J Neural Transm 125, 1217–1223. - PMC - PubMed
    1. Rebholz H, Friedman E, Castello J (2018) Alterations of expression of the serotonin 5-HT4 receptor in brain disorders. Int J Mol Sci 19, 3581. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources